Characterization of genetic changes associated with daptomycin nonsusceptibility in *Staphylococcus aureus*

Zhuo Ma1, Erica Lasek-Nesselquist2, Jackson Lu1, Ryan Schneider2, Riddhi Shah1, George Oliva1, Janice Pata2, Kathleen McDonough2, Manjunath P. Pai1, Warren E. Rose3, George Sakoulas4, Meenakshi Malik1*

1 Albany College of Pharmacy and Health Sciences, Albany, New York, United States of America, 2 Wadsworth Center, New York State Department of Health, Albany, New York, United States of America, 3 University of Wisconsin-Madison, School of Pharmacy, Madison, Wisconsin, United States of America, 4 Center for Immunity, Infection & Inflammation, UCSD School of Medicine, La Jolla, California, United States of America

* Meenakshi.Malik@acphs.edu

Abstract

The extensive use of daptomycin (DAP) for treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) infections in the last decade has led to the emergence of DAP non-susceptible (DNS) *Staphylococcus aureus* strains. A better understanding of the molecular changes underlying DAP-non-susceptibility is required for early diagnosis and intervention with alternate combination therapies. The phenotypic changes associated with DNS strains have been well established. However, the genotypic changes—especially the kinetics of expression of the genes responsible for DAP-non-susceptibility are not well understood. In this study, we used three clinically derived isogenic pairs of DAP-susceptible (DAP-S) and DNS *S. aureus* strains to study gene expression profiles with the objective of identifying the potential genotypic changes associated with DAP-nonsusceptibility. We determined the expression profiles of genes involved in cell membrane (CM) charge, autolysis, cell wall (CW) synthesis, and penicillin binding proteins in DAP-S and DNS isogenic pairs. Our results demonstrate characteristic expression profiles for *mprF*, *dltABCD*, *vraS*, *femB*, and *pbp2a* genes, which are common to all the DNS *S. aureus* strains tested. Whole genome sequencing of DAP-S and DNS clinical isolates of *S. aureus* showed non-synonymous mutations in all DNS strains in genes involved in CM charge, CM composition, CW thickness and CW composition. To conclude, this study unravels some of the complex molecular changes involved in the development of DAP-nonsusceptibility by demonstrating distinct differences in gene expression profiles and mutations in the DNS *S. aureus* strains. This knowledge will aid in rapid identification of DNS *S. aureus* in clinical settings.
Introduction

The past decade has seen a steep rise in antibiotic resistance amongst Gram-positive bacterial pathogens including *Staphylococcus aureus*. Reports indicate that 95% of the clinical isolates of *S. aureus* in the USA are penicillin resistant and more than 50% are methicillin resistant (MRSA) [1]. In addition to MRSA, the antibiotic resistance scenario is further complicated by the emergence of vancomycin-resistant *S. aureus* (VRSA) and vancomycin-intermediate *S. aureus* (VISA) strains [2]. As an effective alternative, daptomycin (DAP) was approved for clinical use in the USA in 2003 for treatment of infections caused by methicillin-susceptible (MSSA), MRSA, and VISA strains. In 2006, DAP was approved for the treatment of bacteremia and right sided endocarditis caused by MSSA and MRSA [3]. DAP is a cyclic lipopeptide antibiotic that shows excellent activity against a variety of Gram-positive bacteria. DAP binds irreversibly to the bacterial cell membrane (CM) in a calcium-dependent manner, and cause cell death by disruption and depolarization of CM [4, 5]. DAP also inhibits biosynthesis of cell wall (CW) components such as lipoteichoic acid and interferes with bacterial cell division [6]. In clinical settings; prolonged underdosing of DAP, ineffective penetration of DAP due to infective endocarditis or osteomyelitis, and previous exposure to antimicrobial peptides or glycopeptide antimicrobials have resulted in emergence of DAP non-susceptible (DNS) *S. aureus* strains [7–10].

Extensive use of DAP for treatment of infections caused by MRSA and VISA has resulted in evolution of DNS *S. aureus* strains [11–15]. The DAP-nonsusceptibility is associated with several phenotypic as well as genotypic changes [16]. The phenotypic changes in DNS *S. aureus* strains include enhanced positive cell surface charge [11, 17] due to increase in positively charged lysyl-phosphatidyl glycerol (L-PG) phospholipids [18, 19], increased CW thickness due to increased teichoic acid synthesis, and altered CM fluidity due to changes in the fatty acid composition [4, 20, 21]. These phenotypic changes result from single or multiple genotypic changes. Mutation and increased transcription of the *mprF* gene; an L-PG synthase results in increased production of L-PG and enhancement of the net cell surface positive charge [22–24]. Mutations in the *dltABCD* operon similar to *mprF* result in increased CM positive charge [25]. Mutation of *walK* gene that encodes a histidine kinase sensor [18, 26] and *csi2*; a cardiolipin synthase [27] alter CW metabolism, cell permeability [28], and cause accumulation of phosphatidyl glycerol [29], respectively. These changes eventually contribute to the development of DNS *S. aureus*. Taken together, these studies have established the phenotypic and genetic changes associated with DNS in *S. aureus*. However, the kinetics and alterations in the expression of genes responsible for causing these changes have not been well characterized.

In this study, we evaluated the expression profile of genes involved in CM charge, autolysis, CW synthesis and penicillin binding proteins using three DAP-S/DNS isogenic pairs A6300/A6298, R6837/R6838 JH1/JH4-JH5 isolated from patients. These strains are derivative of a major MRSA clone USA100. The A6300/A6298 isogenic pair was isolated from a case of bacteremia and prosthetic joint infection in a hospital in Massachusetts. A6300 is a MRSA strain that later developed heteroresistance to vancomycin during vancomycin therapy and a small increase in minimum inhibitory concentration (MIC) to DAP into a non-susceptible range, and was designated as A6298 [30]. The isogenic pairs R6837/R6838 originally described as D592/D712, were isolated from a patient with prolonged bacteremia secondary to osteomyelitis isolated at Westchester Medical Center in Valhalla, New York. The parent R6837 (D592) strain is DAP-S, MRSA and hVISA strain that subsequently mutated to R6838 (D712) as DNS, MRSA, VISA following a 20-day period of vancomycin and DAP therapy [31, 32]. JH1 and JH4 are among the series of isolates recovered from a congenital heart disease patient following
treatment failure with vancomycin, rifampin and imipenem in Baltimore, MD [33]. JH1 recovered before the beginning of DAP antibiotic therapy is fully sensitive to vancomycin, while the subsequent isolates from the same patient recovered after the initiation of vancomycin therapy showed decreased susceptibility to vancomycin as well as DAP. The MIC of JH1 for DAP was 0.01μg/mL, while it increased to 0.05μg/mL for JH2 and subsequent isolates [34]. Although related genetically, the clinical isolates selected for this study are very distinct clinically and microbiologically. The development of DAP-nonsusceptibility in these strains occurred as separate events. In A6298 and JH4 DNS strains, the DAP-nonsusceptibility occurred even before DAP was introduced for clinical use. On the other hand, R6838 developed into a DNS S. aureus following a 3-week exposure to DAP. In this study, we investigated the expression profile of genes and mutations associated with DAP-nonsusceptibility by whole genome sequencing to identify genotypic changes that can serve as markers for differentiation of DAP-S and DNS clinical isolates.

Material and methods

Bacterial strains and antibiotic

Isogenic pairs of susceptible parent strains of DAP-S and DNS A6300/A6298 isolated from a patient suffering from bacteremia and prosthetic joint infection in a hospital in Massachusetts [30], R6837/R6838 isolated from a patient at Westchester Medical Center, New York [31], and JH1/JH4 isogenic pair recovered from a congenital heart disease patient following treatment failure with vancomycin rifampin and imipenem at Johns Hopkins in Baltimore, MD [34]. The reference S. aureus subsp. aureus Rosenbach strain (ATCC® 29213®) was obtained from BEI Resources, Manassas, VA.

Clinical grade Cubicin® (injectable daptomycin) was purchased from Albany Medical Center Outpatient Pharmacy, Albany, NY. The DAP was supplied as 500 mg vials and was reconstituted in sterile water to achieve desired concentrations to be used in various experiments.

Bacterial growth curves

Isogenic DAP-S and DNS pairs A6300/A6298, R6837/R6838 and JH1/JH4, JH5 of S. aureus were streaked on Trypticase™ Soy Agar II with 5% sheep blood (BD Biosciences) using sterile loops and incubated overnight at 37˚C with 5% CO₂. The colonies were resuspended in 10mL of Muller Hinton Broth (BD BBL™) and the optical density (OD₆₀₀) was adjusted at ~0.01. The cultures were grown in a shaking incubator at 37˚C. Aliquots were collected at 1 hour intervals for a period of 8 hours. The aliquots were diluted 10-fold and plated on sheep blood agar plates to quantify bacterial numbers. The plates were incubated at 37˚C overnight. The colonies were counted and the results were expressed as Log₁₀ CFU/mL.

Antimicrobial susceptibility studies

The minimum inhibitory concentration (MIC) values were determined for each DAP-S/DNS S. aureus isogenic pair using either Epsilometer test (E-test) or broth microdilution method. The MIC was considered to be the lowest concentration of the drug required to inhibit bacterial growth. All susceptibility testing was performed in triplicate and was repeated at least twice. For E-test cation-adjusted Muller-Hinton Broth (CAMHB) containing 25mg/mL calcium and 12.5 mg/mL magnesium was used to grow isogenic pairs of DAP-S and DNS S. aureus strains to an OD₆₀₀ of 0.08–0.09 in 5 mL tubes. Sterile cotton swabs were used to uniformly streak a lawn of each clinical isolate on trypticase soy agar plates containing 5% sheep blood. The cultures were allowed to be completely adsorbed. Using sterile tweezers, the E-test
strips containing varying concentrations of DAP (BioMérieux Inc.) were placed on the streaked agar plates. The plates were incubated at 37˚C for 18–20 hours. The elliptical zones of inhibition were read to determine the MIC.

The broth dilution method was performed according to Clinical Laboratory Standards Institute (CLSI) guidelines. Blood agar plates streaked with isogenic pairs of DAP-S and DNS S. aureus strains and a control ATCC® 29213 were grown overnight. Single colonies were picked, inoculated in CAMHB and grown to achieve an OD range of 0.08–0.09 in 5-mL which corresponds to 10^8 CFU/mL. DAP was diluted to a starting concentration of 32 μg/mL of DAP and then diluted two-fold in a sterile 96-well plate to achieve a final concentration of 8, 4, 2, 1, 0.5, 0.25, and 0 μg/mL. In accordance with CLSI standards, bacterial suspension diluted to a final concentration of 5.5x10^5 CFU/mL was added to each well of the plate containing varying concentrations of DAP. After the drug and bacterial inoculum were added, the 96-well plate was incubated for 24 hours and read.

Quantitative real-time polymerase chain reaction (qRT-PCR)

DAP-S and DNS strains grown to a mid-logarithmic phase in MHB were used in all the experiments. The aliquots were collected after 0, 2, 6, and 24 hours of growth for RNA isolation. Isolation of RNA was carried out using the RNA isolation PureLink kit (Invitrogen) according to the manufacturer’s instructions. Two-step qRT-PCR was carried out by first generating the cDNA using the BioRad® iScript™ cDNA kit and then performing the qRT-PCR assay using the BioRad iQSYBR Green Supermix kit. The primer sequences used for transcriptional analysis of genes are shown in Table 1. Normalization of the target gene was done using 16S rRNA as an internal control.

Transmission electron microscopy (TEM)

TEM was conducted using a previously published protocol. A Philips CM120 electron microscope with Image 1.39t software was used to measure and analyze CW thickness and differences in septum formation between DAP-S and DNS S. aureus clinical isolates. Each strain was streaked on blood agar and incubated overnight at 37˚C. The following day, 1–2 colonies from the incubated plates were inoculated in MHB and incubated overnight. The bacterial cultures were centrifuged and the pellets were washed with cold sodium phosphate buffer. The pellets were fixed in electron microscopy buffer, post-fixed in 1% osmium tetroxide, dehydrated and embedded in Spurr’s epoxy resin. Ultrathin sections of the samples were examined using the electron microscope. CW thickness was measured from each quadrant of the cell on a minimum of 25 cells.

CM fluidity assay

Membrane fluidity of DAP-S and DNS clinical isolates was determined spectrofluorometrically using a fluorescent probe, 1,6-diphenyl-1,3,5-hexatriene (DPH) as described previously [20]. Briefly, the overnight cultures were inoculated in fresh MHB medium and grown to an OD_{600} between 0.2–0.5. Then, bacterial cells were pelleted, washed with normal saline (0.85% NaCl) and resuspended to an OD_{600} of 0.3 in normal saline (0.85% NaCl) containing 2μM DPH. The DPH suspension was incubated for an hour at 37˚C and transferred to preheated cuvettes. The fluorescence was determined in an ISS Koala spectrofluorometer with a temperature-controlled cuvette holder maintained at 37˚C. The excitation and emission wavelengths for DPH were 360 nm and 426 nm, respectively. The polarization index (p) of each sample was calculated and recorded as described previously [20]. Lower polarization index value is an indicator of higher degree of cell membrane fluidity [35].
Cytochrome C binding assay

Cytochrome C binding assay was carried out as described previously [19, 36, 37]. Briefly, bacterial cells were grown for 24 hours in MHB media and washed twice with 20 mM MOPS buffer (pH 7.0). The cells were adjusted to a final OD \(600\) of 0.150 in the MOPS buffer and then incubated with 0.5mg/mL cytochrome C at room temperature for 10 minutes in a total volume of 500 \(\mu l\). The reaction mixture was centrifuged for 5 minutes and the amount of the unbound cytochrome C was quantified spectrophotometrically at 530nm in the supernatants.

Whole genome sequencing

Overnight cultures of DAP-S and DNS \(S.\) \textit{aureus} clinical isolates were treated with lysostaphin and lysozyme to disrupt the peptidoglycan layer of the CW, genomic DNA isolated using Pure-Link Genomic DNA Mini Kit (Invitrogen), and submitted to the Wadsworth sequencing core. Whole genome sequencing libraries were prepared with the Nextera DNA library preparation kit (Illumina) and sequenced using the standard 500 cycle V2 protocol on an Illumina MiSeq. Whole genome sequences were required to have an average coverage of at least 80x for the genome before analysis.

The subroutine bbduk from bbtools v36.38 (https://sourceforge.net/projects/bbmap) quality trimmed raw Illumina reads and removed any remaining adaptors/primers with the following parameters: qin = 33, ktrim = r, mink = 11, trimq = 20, minlength = 100, tbp = t, and

Table 1. List of primer sequences used for transcriptional analysis.

| Gene | Primer | Sequence |
|------|--------|----------|
| mprF | Forward | 5’ TTA TAG GTT TCG GTG GCT TT 3’ |
|      | Reverse | 5’ GAT GCA TCG AAA ACA TGG AA 3’ |
| dltA | Forward | 5’ TAA CCA AGC GCC ATT TTC AT 3’ |
|      | Reverse | 5’ AAC GCC TCA CTA AGC CTT TT 3’ |
| dltB | Forward | 5’ GCC ATT AGC ACT TGT GAA AGT GT 3’ |
|      | Reverse | 5’ TCC AGA TGA AAT CGT TGG GA 3’ |
| dltC | Forward | 5’ CCA GAC GTA GAA ATT TTT GTA GAA 3’ |
|      | Reverse | 5’ CGT AAC TCT TCT AAT GCT TCA AGC 3’ |
| dltD | Forward | 5’ GCA TTA AAT AGC CAT AAC GCC AAC 3’ |
|      | Reverse | 5’ GAC ATG TTT TTT TGC TGG AGA C 3’ |
| vraSR | Forward | 5’ TGC TTA CAG AAC GAG AAA TGG AAA 3’ |
|      | Reverse | 5’ CGT TTT AAT AGT CGA TGC A 3’ |
| femA | Forward | 5’ GA TCC ATA AAG GAT TTT ACG CTG 3’ |
|      | Reverse | 5’ AAG GTA CTA ACA CAC GGT CTT TG 3’ |
| femB | Forward | 5’ CCT TGA AGG TAA AAC ACC CGA 3’ |
|      | Reverse | 5’ GTC ATT CAA TTC CTG TTG CAA CT 3’ |
| walKR | Forward | 5’ ACT TGT GGC ATG TAC GTA CG 3’ |
|      | Reverse | 5’ AGC CCG ATA ATT TGC ATA CC 3’ |
| Atl  | Forward | 5’ ACA ACG CAC GGA TTA CAC ATG T 3’ |
|      | Reverse | 5’ CCG ATA AAC ATT GAC ATC TTG C 3’ |
| lytM | Forward | 5’ CGA GTC AAA GCC AAC AGC ATA T 3’ |
|      | Reverse | 5’ TTT CAG GCA TTG CAT AGT C 3’ |
| Pbp2a | Forward | 5’ TTT TGG CCA ACC TTT ACC ATC G 3’ |
|      | Reverse | 5’ TAC TGC TAT CCA CCC TCA AACA 3’ |
| Pbp1 | Forward | 5’ AGG TAG CGG TTT TTG GTG C 3’ |
|      | Reverse | 5’ TAT CCT TGT CAG TTT TAC TGT C 3’ |

https://doi.org/10.1371/journal.pone.0198366.t001
tpe = t. BWA v.0.7.5 [38] with the “mem” option aligned processed reads for all isogenic pairs to the N315 genome (BA000018.3). Additionally, reads from JH4 and JH5 resistant strains were aligned to their JH1 parental genome (RefSeq accession number GCF_000017125.1) and reads from A6298 were aligned to the susceptible parental A6300 genome (RefSeq accession number GCF_000174515.1). Because the R6837/R6838 clinical pair lacked a representative genome in GenBank, we aligned R6838 reads to a de novo assembly of R6837, which was produced by Spades v.3.8.0 [39] and annotated by Prokka v1.1 [40]. Reads from R6837 and R6838 were also aligned to the Mu50 genome (BA000017.4) to confirm the presence of SNPs identified by Werth et al., 2013 [32]. SAMtools/BCFtools 0.1.19 [41] detected SNPs from each reference alignment by considering base positions with a Phred score > = 20 and reads with a minimum mapping score of 20. We only analyzed SNPs at positions covered by a depth of 20 or more reads and where 95% of the reads supported the alternative allele. The presence of each potential SNP/Indel and its quality were confirmed in IGV v.2.3.78 [42] and mutations that occurred in highly variable regions (such as phage insertions) were discarded. Custom designed Python scripts associated mutations with coding or non-coding regions to identify changes potentially involved in DNS and to confirm the presence of previously recorded SNPs/Indels.

**Statistical analysis**

Statistical analysis of all results was performed using GraphPad InStat Software Version 3.05. Analysis was carried out using one-way ANOVA with Tukey-Kramer post-test where appropriate and a $P$ value of 0.05 or less was considered significant.

**Results**

**DNS strains A6298, R6838 and JH4 have growth characteristics similar to their DAP-S parent strains, but exhibit increased MIC for DAP**

The three isogenic DAP-S/DNS pairs (A6300/A6298; R6837/R6838 and JH1/JH4) were characterized for their growth characteristics and susceptibility to DAP by generating bacterial growth curves, and colony counts at various time intervals. It was observed that growth of the isogenic DNS strains A6298, R6838 and JH4 was similar to their respective parent DAP-S strains A6300, R6837 and JH1 determined either by OD$_{600}$ values or CFUs indicating that all the DAP-S/DNS isogenic pairs have identical growth patterns (Fig 1A and 1B).

The MICs of DAP for the isogenic DAP-S/DNS pairs was determined by broth microdilution assay and E-test. The DNS strains A6298, R6838 and JH4 exhibited 2-4-fold increase in MIC values as compared to their parent DAP-S strains A6300, R6837 and JH1. The E-test revealed a similar 2-5-fold increase in MIC for DAP for the DNS S. aureus strains (Fig 1C). Collectively, these results indicate that the DNS S. aureus strains have developed non-susceptibility to DAP however, their in vitro growth attributes remain unaltered.

**DAP-nonsusceptibility in S. aureus strains is associated with minor phenotypic changes**

Since CW thickness and cell morphology differences have often been associated with DNS, we next determined if the DAP-S parent strain R6837, and its non-susceptible counterpart R6838 exhibit any such differences. Cell morphology differences in septation and CW thickness between the isogenic DAP-S and DNS S. aureus isolates were examined by TEM. No difference in mean CW thickness was observed between DAP-S and DNS S. aureus strains (44.7±8.6 nm versus 43.8±6.6 nm, respectively). However, DNS R6838 strain displayed a significant increase
in the percentage of cells with partial or complete septae. After overnight growth, 57.1% of R6838 cells showed septa formations as compared to 29.1% of the DAP-S R6837 isolate (Fig 2A). These results indicate that the septae formation is increased in DNS as compared to the DAP-S S. aureus strains.

Several reports have demonstrated an association between CM fluidity and DNS. The CM fluidity of all the three isogenic pairs of clinical isolates of DAP-S and DNS S. aureus strains were determined spectrofluorometrically using a fluorescent probe according to a previously published protocol [35]. The isogenic DNS S. aureus strains A6298 and JH4 exhibited increased membrane fluidity as compared to their DAP-S parent strains (Fig 2B). However, these differences did not achieve statistical significance. We also determined the changes in the cell surface charge of the DAP-S and DNS S. aureus strains. The reduced binding of the cytochrome C indicates an enhanced positive charge on cell surface envelop [37]. It was observed that a higher percentage of unbound cytochrome C was detected in supernatants from DNS S. aureus A6298, R6838 and JH4 strains as compared to their DAP-S counterparts A6300, R6837 and JH1, respectively (Fig 2C). These results indicate an increased cell surface positivity in DNS as
compared to the DAP-S strains. Collectively, these results demonstrate that the DNS in S. aureus is associated with increased septations and cell surface charge but not with enhanced CW thickness or CM fluidity.

DNS S. aureus strains exhibit alterations in the expression of genes involved in maintenance of CM charge

One of the key genes involved in regulating the cell surface charge is the multipeptide resistance factor (mprF) gene. We investigated the expression of mprF gene in the three isogenic pairs of DAP-S and DNS S. aureus strains. Significantly elevated expression of the mprF gene was observed in DNS S. aureus strains A6298 and R6838 as compared to their isogenic parent DAP-S strains A6300 and R6837, respectively, after 24 hrs of growth. Although the mprF transcript levels were elevated after 24 hrs of growth in the DNS JH4 strain as compared to its isogenic DAP-S parent strain JH1, the statistical significance was not achieved (Fig 3).
Genetic mechanisms of daptomycin nonsusceptibility of *S. aureus*
Another group of genes that are involved in increasing the cell surface charge are those encoded on the *dltABCD* operon. Significantly elevated levels of *dltA*, *dltB*, *dltC* and *dltD* genes were observed in all DNS *S. aureus* strains as compared to their DAP-S parents after 24 hours of growth (Fig 4A–4D). These results indicate that the expression of genes involved in maintaining the cell surface charge are significantly upregulated in the DNS *S. aureus* strains.

**DNS S. aureus strains exhibit differential expression of genes involved in CW synthesis**

CW synthesis is mainly regulated by positive and negative feedback of specific genes. Two regulatory operons responsible for the synthesis of the CW are *vraSR* and *walK*. The transcription
of CW synthesis-associated vraSR gene was analyzed by qRT-PCR. The transcript levels of vraSR gene were significantly upregulated in all DNS S. aureus strains as compared to the DAP-S parent strains after 24 hours of growth, but the extent of upregulation varied (Fig 5A).

WalKR (also known as yycGF) acts as the master controller of peptidoglycan metabolism, regulates fatty acid biosynthesis, and controls the activity of major autolysins genes atl and lytM. We found no significant alterations in the levels of walKR transcripts in DNS as compared to the DAP-S S. aureus strains after 2 hours of growth. However, the walKR transcript levels were down regulated in both DAP-S and DNS S. aureus strains after 6 and 24 hours of growth (Fig 5B).

Additionally, factors essential for methicillin resistance (fem) also play a key role in developing resistance. We determined the expression profiles of femA and femB genes, which remained unaltered and no differences were observed between the DAP-S and DNS S. aureus strains (Fig 6A and 6B).

Expression of penicillin binding proteins (PBPs) is altered in DNS S. aureus strains

The antibacterial activity of beta-lactam antibiotics results from their covalent binding to the active sites of PBPs. Susceptible strains of S. aureus produce PBP1, PBP2, PBP3 and PBP4; however, MRSA strains produce abundant PBP2a protein, a transpeptidase to which most beta-lactam antibiotics cannot bind and therefore cannot exert their antibacterial actions. We investigated the expression of php1 and php2a genes in DAP-S and DNS S. aureus strains. The expression levels of php1 downregulated as the growth progressed in all the isogenic pairs of DAP-S and DNS S. aureus strains tested (Fig 7A). On the other hand, the DNS S. aureus strains (A6298, R6838 and JH4) revealed significantly elevated expression of the php2a gene as compared to the DAP-S strains (A6300, R6837 and JH1) after 24 hours of growth (Fig 7B). These results suggest that both DAP-S and DNS S. aureus strains maintain their resistance to beta-lactam antibiotics by reducing the expression of genes required for optimal attachment and binding. In addition, the DNS S. aureus strains upregulate php2a expression.
DNS S. aureus strains exhibit upregulated expression of genes involved in autolysis

Differences in the expression of autolysis genes *atl* and *lytM* have been reported to contribute to DAP non-susceptibility. We determined the expression of *atl* and *lytM* genes in DAP-S and DNS *S. aureus* strains. We observed significantly higher transcript levels of *atl* gene in all DNS *S. aureus* strains after 24 hours of growth as compared to the DAP-S strains (Fig 8A). Similarly, we observed significantly higher transcript levels of *lytM* gene in the DNS strains.

---

**Fig 6.** DAP-S or DNS *S. aureus* strains do not exhibit altered expression of *femA* and *femB* genes involved in CW synthesis. Expression profile of (A) *femA* and (B) *femB* genes at the indicated times of bacterial growth by qRT-PCR. 16S rRNA was used as an internal control. Results are representative of at least two independent experiments performed.

https://doi.org/10.1371/journal.pone.0198366.g006

**DNS S. aureus** strains exhibit upregulated expression of genes involved in autolysis

Differences in the expression of autolysis genes *atl* and *lytM* have been reported to contribute to DAP non-susceptibility. We determined the expression of *atl* and *lytM* genes in DAP-S and DNS *S. aureus* strains. We observed significantly higher transcript levels of *atl* gene in all DNS *S. aureus* strains after 24 hours of growth as compared to the DAP-S strains (Fig 8A). Similarly, we observed significantly higher transcript levels of *lytM* gene in the DNS strains.

---

**Fig 7.** Expression of penicillin binding proteins (PBP) is altered in DNS *S. aureus* strains. Expression profile of (A) *pbp1* and (B) *pbp2a* genes at the indicated times of bacterial growth by quantitative qRT-PCR. 16S rRNA was used as an internal control. Results are representative of at least two independent experiments. Statistical analysis was carried out using one-way ANOVA and a *P* value of 0.05 or less was considered significant. **P** < 0.01, ***P** < 0.001.

https://doi.org/10.1371/journal.pone.0198366.g007
A6298 and JH4, but not in R6838 as compared to the DAP-S strains A6300, JH1 and R6837 (Fig 8B).

Mutations observed in DNS S. aureus strains

Whole genome sequencing was performed to identify mutations, which may contribute to DAP-nonsusceptibility in S. aureus strains as compared to their DAP-S isogenic counterparts. All single nucleotide polymorphisms (SNPs) detected by aligning the DNS strains to their DAP-S isogenic mate were also identified by isogenic pair alignments to the reference S. aureus strains N315 and Mu50, indicating a consistency of our results regardless of the reference genome employed. We identified most mutations that were previously reported for JH4, JH5, R6838, and A6298 strains [32, 43, 44], further confirming the quality of our results. Additionally, we detected novel mutations not identified in the previous studies, including two nonsynonymous mutations within the 50S ribosomal L3 protein (gene SA2047) in both the JH4 and JH5 strains, two substitutions upstream of lysine decarboxylase gene (SA0439) in JH4, and a nonsynonymous substitution in the vraG gene of JH5. However, we did not detect a nonsynonymous mutation reported in the SA20124 gene of A6298 [44] or a 9 base pair deletion identified in the SA1249 gene of JH5 strains [34]. Comparisons of the mutations from DNS strains for identification of genetic markers for vancomycin and DNS did not reveal any common mutations except for the JH4 strain (Table 2).

Discussion

In the recent past, DNS S. aureus strains resulting from treatment failures have been increasingly reported [45]. Cases of refractory bacteremia persisting for days or even weeks treated initially with vancomycin and subsequently with DAP, in association with host innate immune system and antimicrobial therapy provide a selective pressure for emergence of DNS S. aureus. Unlike phenotypic changes associated with the DNS S. aureus strains, the genotypic changes, especially the kinetics of alterations in the expression of genes responsible for causing DAP-nonsusceptibility are not well understood. In this study, we investigated the expression profiles of
Table 2. Mutational differences between DNS and DAP-S isogenic strain pairs identified by whole genome sequencing.

| Isogenic pair (DAP-S/ DNS) | Mutation position | Mutation type | Locus abbreviation/ Gene name | Locus description | Notes |
|----------------------------|-------------------|---------------|--------------------------------|-------------------|-------|
| A6300/ A6298              | 649970            | Synonymous F147F<sup>a</sup> | SA0556                         | Conserved hypothetical protein | [44] |
|                           | 670496            | Synonymous G174G | SA0578                         | NADH dehydrogenase |       |
| A6300/ A6298              | 802280            | Noncoding      | SA0704                         | Conserved hypothetical protein |       |
| A6300/ A6298              | 1052756           | Nonsynonymous V353A<sup>a</sup> | purD/SA0926                     | Phosphoribosylamine—glycine ligase PurD | [44] |
| A6300/ A6298              | 1604155           | Nonsynonymous E66K<sup>a</sup> | SA0578                         | Diacylglycerol kinase | [44] |
| A6300/ A6298              | 1700172           | Nonsynonymous G49D<sup>a</sup> | hemL/SA1491                     | Guttamate-1-semialdehyde 2% 2C1-aminomutase | [44] |
| A6300/ A6298              | 2792195           | Nonsynonymous N83S<sup>a</sup> | drp35/SA2480                    | Drp35 |       |
| R6837/ R6838              | 1364633           | Nonsynonymous L341S<sup>a</sup> | mprF/SA1193                     | Oxacillin resistance-related MprF protein | Same as Mu50 position 1440962 in gene SAV1360 [32] |
| R6837/ R6838              | 1532504           | Synonymous I34I<sup>a</sup> | srrB/SA1322                     | Staphyloccocal respiratory response protein SrrB | Same as Mu50 position 1608916 in gene SAV1491 [32] |
| R6837/ R6838              | 1882832           | Noncoding<sup>a</sup> | SA1649                         | Conserved hypothetical protein | Same as Mu50 position 1960627 [32] |
|                           | 2009715           | Noncoding      | SA1759                         | Lytic enzyme | R6838 reversion to N315 reference |
| R6837/ R6838              | 2378757           | Nonsynonymous D31E<sup>a</sup> | SA2115                         | Transcriptional regulator | Same as Mu50 position 2448257 in gene SAV2324, R6838 reversion to N315 reference [32] |
| R6837/ R6838              | 2521688           | Nonsynonymous A151V<sup>a</sup> | SA2244                         | Endo-1,4-beta-glucanase | Same as Mu50 position 2592882 in gene SAV2455 [32] |
| JH1/JH4, JH1/JH5          | 27546             | stop codon at AA 36<sup>a</sup> | SA0019                         | Conserved hypothetical protein | Originally identified in JH6 [34] |
| JH1/JH4                   | 511808            | Noncoding      | SA0439                         | Lysine decarboxylase |       |
| JH1/JH4                   | 511809            | Noncoding      | SA0439                         | Lysine decarboxylase |       |
| JH1/JH4, JH1/JH5          | 581030            | Nonsynonymous D471Y<sup>a</sup> | rpoB/SA0500                     | RNA polymerase beta chain | Originally identified in JH2 [34] |
| JH1/JH4, JH1/JH5          | 581036            | Nonsynonymous A473S<sup>a</sup> | rpoB/SA0500                     | RNA polymerase beta chain | Originally identified in JH2 [34] |
| JH1/JH4, JH1/JH5          | 581048            | Nonsynonymous A477S<sup>a</sup> | rpoB/SA0500                     | RNA polymerase beta chain | Originally identified in JH2 [34] |
| JH1/JH4, JH1/JH5          | 581053            | Nonsynonymous E478D<sup>a</sup> | rpoB/SA0500                     | RNA polymerase beta chain | Originally identified in JH2 [34] |
| JH1/JH4, JH1/JH5          | 585867            | Nonsynonymous E854K<sup>a</sup> | rpoC/SA0501                     | RNA polymerase beta-prime chain | Originally identified in JH2 [34] |
| JH1/JH4, JH1/JH5          | 674706            | Synonymous S305<sup>a</sup> | SA0582                         | Na+/H+ antiporter | Originally identified in JH6 [34] |
| JH1/JH4                   | 792565            | Nonsynonymous Y171C<sup>a</sup> | SA0694                         | Conserved hypothetical protein |       |
| JH1/JH4                   | 810100            | Synonymous I242I<sup>a</sup> | prfB/SA0709                     | Peptide chain release factor 2 |       |
| JH1/JH4                   | 810711            | Noncoding      | SA0710                         | Conserved hypothetical protein |       |
| JH1/JH4, JH1/JH5          | 1110065           | Nonsynonymous A84V<sup>a</sup> | isdE/SA0980                     | Ferrichrome ABC transporter | Originally identified in JH6 [34] |

(Continued)
Table 2. (Continued)

| Isogenic pair (DAP-S/DNS) | Mutation position | Mutation type | Locus abbreviation/ Gene name | Locus description | Notes |
|---------------------------|-------------------|---------------|--------------------------------|------------------|-------|
| JH1/JH4, JH1/JH5         | 1282852           | Nonsynonymous | D296Y                          | SA1129           | Conserved hypothetical protein | Originally identified in JH2 [34] |
| JH1/JH4                   | 1408780           | Noncoding     | CspA/SA1234                    |                  | Major cold shock protein CspA   |
| JH1/JH4                   | 1583224           | Nonsynonymous | L46P                           | SA1378           | Conserved hypothetical protein   |
| JH1/JH4, JH1/JH5          | 1893513           | Frameshift Ax7 deletion<sup>a,b</sup> | prsA/SA1659   | Peptidyl-prolyl cis/trans isomerase | Originally identified in JH6 [34] |
| JH1/JH4, JH1/JH5          | 1948612           | Nonsynonymous | H164R                          | SA1702           | Conserved hypothetical protein   |
| JH1/JH4, JH1/JH5          | 2307851           | Nonsynonymous | G152D                          | prlC/SA2047      | 50S ribosomal protein L3         |
| JH1/JH4, JH1/JH5          | 2307876           | Nonsynonymous | G144S                          | prlC/SA2047      | 50S ribosomal protein L3         |
| JH1/JH4, JH1/JH5          | 2354954           | Nonsynonymous | A94T                           | SA2094           | Na+/H+ antiporter                |
| JH1/JH4, JH1/JH5          | 2391175           | Noncoding<sup>a</sup> | SA2126   | Hypothetical protein              | Originally identified in JH6 [34] |
| JH1/JH4, JH1/JH5          | 2604820           | Synonymous    | D168D                          | SA2320           | Regulatory protein pfoR          |
| JH1/JH4                   | 2630178           | Synonymous    | G242G                          | rocA/SA2341      | 1-pyrroline-5-carboxylate dehydrogenase |
| JH1/JH5                   | 85776             | Synonymous    | Q64Q                           | SA0077           | Serine/threonine protein kinase  |
| JH1/JH5                   | 180296            | Nonsynonymous | E101G                          | capM/SA0156      | Capsular polysaccharide synthesis enzyme Cap5M |
| JH1/JH5                   | 255175            | Nonsynonymous | D197G                          | SA0215           | Two-component response regulator |
| JH1/JH5                   | 396355            | Nonsynonymous | A257V                          | SA0339           | ABC transporter ATP-binding protein |
| JH1/JH5                   | 448576            | Synonymous    | S221S                          | set12/SA0388     | Exotoxin 12                       |
| JH1/JH5                   | 484526            | Stop codon at AA 254 | SA0422   | Lactococcal lipoprotein          |
| JH1/JH5                   | 621945            | Noncoding     | nagB/SA0527                    |                   | Glucosamine-6-phosphate isomerase |
| JH1/JH5                   | 712573            | Nonsynonymous | A580V                          | vraG/SA0617      | ABC transporter permease          |
| JH1/JH5                   | 751554            | Noncoding     | SA0657                         |                   | Hemolysin                         |
| JH1/JH5                   | 1005831           | Nonsynonymous | C147Y                          | SA0885           | Hypothetical protein              |
| JH1/JH5                   | 1893057           | Nonsynonymous | E140Q                          | prsA/SA1659      | Peptidyl-prolyl cis/trans isomerase |
| JH1/JH5                   | 1954969           | Nonsynonymous | D48H                           | SA1708           | UDP-N-acetylmuramyl tripeptide synthetase |
| JH1/JH5                   | 2368738           | Nonsynonymous | H177R                          | SA2105           | Conserved hypothetical protein    |
| JH1/JH5                   | 2382895           | Synonymous    | P247P                          | SA2119           | Dehydrogenase                     |
| JH1/JH5                   | 2393142           | Nonsynonymous | M33T                           | SA2127           | Ribose 5-phosphate isomerase (rpi) |

<sup>a</sup>Mutations identified in previous publications are shown in bold letters.

<sup>b</sup>N<sub>x</sub> number = nucleotide x number of repeats.

https://doi.org/10.1371/journal.pone.0198366.t002
of genes involved in CM charge (mprF, dltABCD), CW synthesis (femA, femB, vraSR, and walKR); autolysis (atl, lytM); and penicillin binding (pbp1 and pbp2a) in three isogenic pairs of DAP-S and DNS S. aureus strains.

It has been postulated that in DNS S. aureus strains a “charge-repulsive milieu” is responsible for repulsion/non-binding of DAP-calcium complex [46]. Reports suggest that the mprF and dlt genes of S. aureus act by increasing the net surface positive charge [11, 19]. The mprF gene alters the net surface charge by lysylating the membrane PG to generate a positively-charged L-PG which ultimately translocate to the outer membrane leaflet. Unlike mprF, the dltABCD operon acts by D-alanylation of CW teichoic acids creating a greater net positive charge, thereby reducing the access of DAP to the CM [4, 19, 23]. The increased expression of mprF gene has been reported to be associated with enhanced DNS [15, 22, 47]. S. aureus strains exhibiting gain-of-function mprF mutations have increased positive cell surface charge and reduced capacity to bind DAP [11]. Consistent with these findings, we observed significantly elevated expression of the mprF and dltABCD operon genes in DNS S. aureus strains indicating that increased expression of mprF, and dlt operon genes may cause an increased positive cell surface charge and reduced binding of DAP, thereby contributing to non-susceptibility. These findings were also corroborated by an enhanced positive charge in the DNS S. aureus strains in cytochrome C binding assays. The enhanced expression of mprF gene DNS S. aureus strains is akin to the “gain in mprF function” associated with mutations in mprF gene [48].

The “membrane order hypothesis” associates phenotypic adaptations that include alterations in the composition of CM fatty acids, and enhanced CW teichoic acids and peptidoglycan synthesis resulting in increased CM fluidity [21, 49] and CW thickness [4, 50], respectively. Consistent with these observations, we demonstrate an increased expression of vraSR gene in DNS as compared to DAP-S S. aureus strains. Bertsche et al., 2013 demonstrated a correlation between thickened CW and increased cell surface charge [4]. CW thickening, however, has been shown to be sufficient but not necessary for development of DNS [15, 17, 51].

VraSR and walKR/yyCGF/vicRK are two-component regulatory systems which regulate CW biosynthesis [52]. Over expression of vraSR in DAP-S strains is associated with increased DAP-nonsusceptibility [47]. Consistent with previous reports [15, 17], despite an upregulated expression of vraSR in the DNS S. aureus strains, the CW thickness remained unchanged in DAP-S and DNS isogenic strains (Fig 2A). WalKR is the master controller of peptidoglycan metabolism and its depletion leads to CW thickening and defects in cell division due to its role in coordination of CW metabolism and cell division [53]. WalKR also controls the activity of major autolyisin genes atl and lytM [54]. The atl gene encodes a bi-functional enzyme with an amidase and a glucosaminidase domain that represents the most predominant peptidoglycan hydrolase of S. aureus; whereas the lytM gene encodes a Gly-Gly endopeptidase. Song et al., 2013 demonstrated a lower rate of autolysis in the DNS strain [55]. It is worth noting that upregulation of the autolytic genes atlA and lytM in the DNS S. aureus strains indicate an autolytic cell death unlike that observed for DAP-S counterparts. Collectively, these results demonstrate that the major mechanism of DNS in S. aureus strains appears to be due to the alteration of expression of genes involved in maintenance of cell surface charge rather than those involved in increasing the CW thickness.

Another important finding from the study was differential expression of PBP genes in DAP-S and DNS S. aureus strains. Thus, it was interesting to observe that the DNS strains had significantly elevated expression of pbp2a gene as compared to the DAP-S strain even in the drug free conditions of our study. On the other hand, the expression of pbp1 was significantly downregulated in both DAP-S as well as DNS S. aureus strains. PBP1 is located in the septum and plays an important role in cell division of S. aureus [56]. Our analysis of cells by TEM found a greater percentage of cells with septum formation in DNS R6838 strain. Since
expression of PBP1 was downregulated over time in both DAP-S and DNS strains, it is our hypothesis that PBP1 may be important for the completion of cell division, but perhaps not required for septa initiation. Thus, reduced PBP1 may leave partially initiated septae that do not result in cell division.

Several reports suggest that genetic mutations are important for conferring DNS [55, 57]. Mutations in the CW synthesis genes (mprF, agrC), RNA polymerases (rplV, rplC), two component systems (walKR/vicR), and proteases (clpP) have been associated with antibiotic resistance [58]. In our study, all DNS clinical strains sequenced had non-synonymous mutations in genes that could ultimately alter CM charge, CW thickness and CW composition. The whole genome sequencing analysis revealed several new SNPs in DNS strains, including two non-synonymous mutations within the 50S ribosomal L3 protein (gene SA2047) of both the JH4 and JH5 strains, two substitutions in the JH4 strain upstream of a lysine decarboxylase (SA0439) gene which potentially interacts with BlaR1; the integral membrane protein that confers β-lactam resistance [59], and a non-synonymous substitution in the vraG gene of JH5 strain. The vraG gene is part of the vraFG locus, which is an ABC transporter-dependent efflux pump and is located downstream of a two-component regulatory system, GraRS. Co-transcription of both the vraG and graR is required for the expression of mprF and dlt genes which play an important role in maintaining net positive surface charge and resistance to cationic antimicrobial peptides [22]. Furthermore, Mwangi et al., 2013 [43] observed a progression of mutations from strains JH1-JH9 that correlated with increasing antibiotic resistance, we detected a majority of the mutations that were reported for JH6 were present in JH4 and JH5 strains. We believe that this is possibly due to the increased depth of the sequence coverage provided by Illumina sequencing and suggests that mutations do not necessarily occur in a sequential order. Mutations in yycH, which controls CW and CM turnover through the essential two component WalKR system, were observed in both the DNS JH4 and JH5 strains of S. aureus [43, 60, 61]. Mutations in rpo genes were also observed in JH4 and JH5 isolates. While mutations in rpo genes are not thought to directly contribute to antibiotic resistance, they may adjust the global transcriptional profile and develop DNS phenotype [62, 63]. DNS isolate A6298 was additionally found to have a mutation in dgkA gene, which encodes undecaprenol kinase (UDPK). UDPK recycles undecaprenol by phosphorylation to form undecaprenol phosphate (bactoprenol) which is a precursor of lipid carriers involved in CW biogenesis [64, 65]. Another DNS isolate R6838 harbored a mutation in the phosphatidylglycerol lysistransferase (mprF), which adds a positively charged lysine residue to PG and flips L-PG into the outer membrane. The mprF mutations in clinical DNS isolates including the mutations that corresponds to L341S mutation in R6838 isolate observed in this study [66]. This mutation is in the bifunctional domain of mprF, which could impact L-PG content in the CM, changing the net membrane charge and resulting in DNS in combination with expression changes [14].

Our DNA sequence analysis also revealed that resistance to vancomycin and DAP evolves in multiple ways as none of the resistant strains showed identical mutations except for JH4 and JH5 which are derived from the same parent. Thus, our results further establish the notion that multiple genetic mechanisms are involved in the development of DNS in S. aureus. It is noteworthy to mention that the manner in which the development of DAP resistance occurred in DNS S. aureus strains varied. The JH4-JH5 and A6298 DNS strains were derived from patients that were never treated with DAP. This resistance has been reported to occur in response to host’s cationic antimicrobial peptides which may provide an endogenous selection pressure for the development of DAP-nonsusceptibility [6]. However, the DAP-nonsusceptibility in R6838 strain was observed while the patient was on DAP therapy following treatment failure with vancomycin. These observations indicate that both the endogenous and exogenous antimicrobial selection pressure may play an important role in the development of DNS in S. aureus.
Taken together, this study unravels some of the complex molecular changes involved in the development of DNS and demonstrates that differences in gene expression profiles and mutational differences in the DNS *S. aureus* strains can serve as markers for differentiation of DAP-S and DNS *S. aureus* in clinical settings.

**Acknowledgments**

This study was supported by "Investment in Collaborative Research at the Wadsworth Center and Albany College of Pharmacy and Health Sciences Grant". The funders had no role in the design or execution of the experiments. The authors acknowledge Wadsworth Center Applied Genomics Technologies and Bioinformatics & Statistics Cores for providing technical support.

**Author Contributions**

**Conceptualization:** Kathleen McDonough, Manjunath P. Pai, Meenakshi Malik.

**Formal analysis:** Zhuo Ma, Erica Lasek-Nesselquist, Meenakshi Malik.

**Funding acquisition:** Manjunath P. Pai, Meenakshi Malik.

**Investigation:** Zhuo Ma, Ryan Schneider, Janice Pata, Warren E. Rose, George Sakoulas.

**Methodology:** Zhuo Ma, Jackson Lu, Ryan Schneider, Riddhi Shah, George Oliva, Warren E. Rose, George Sakoulas.

**Resources:** Warren E. Rose, George Sakoulas.

**Supervision:** Janice Pata, Kathleen McDonough, Meenakshi Malik.

**Writing – original draft:** Zhuo Ma, Meenakshi Malik.

**References**

1. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med. 1999; 20(2):303–16. viii. PMID: 10386258

2. Bulchandani D, Nachnani J, Fitzsimmons C, Jost P, Brewer J. Beyond MRSA: the growing menace of hVISA and VISA. South Med J. 2008; 101(6):663–4. https://doi.org/10.1097/SMJ.0b013e31817216f1 PMID: 1852225

3. Eisenstein BI, Oleson FB Jr., Baltz RH. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis. 2010; 50 Suppl 1:S10–5. Epub 2010/01/14. https://doi.org/10.1086/647938 PMID: 20067387.

4. Bertsche U, Yang SJ, Kuehner D, Wanner S, Mishra NN, Roth T, et al. Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant *Staphylococcus aureus* (MRSA) clinical isolates. PLoS One. 2013; 8(6):e67398. https://doi.org/10.1371/journal.pone.0067398 PMID: 23785522

5. Alder J. The use of daptomycin for *Staphylococcus aureus* infections in critical care medicine. Crit Care Clin. 2008; 24(2):349–34x. https://doi.org/10.1016/j.ccc.2007.12.010 PMID: 18361990

6. Canepari P, Boaretti M, Lleo MM, Satta G. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother. 1990; 34(6):1220–6. Epub 1990/06/01. PMID: 2168145; PubMed Central PMCID: PMCPMC171768.

7. Chambers HF, Deleo FR. Waves of resistance: *Staphylococcus aureus* in the antibiotic era. Nat Rev Microbiol. 2009; 7(9):629–41. https://doi.org/10.1038/nrmicro2200 PMID: 19680247

8. Parra-Ruiz J, Vidaillic C, Rose WE, Rybak MJ. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of *Staphylococcus aureus* biofilm. Antimicrob Agents Chemother. 2010; 54(10):4329–34. Epub 2010/08/11. https://doi.org/10.1128/AAC.00455-10 PMID: 20696880; PubMed Central PMCID: PMCPMC2944618.

9. Traunmuller F, Schintler MV, Metzler J, Spende S, Mauric O, Popovic M, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother. 2010; 65(6):1252–7. Epub 2010/04/09. https://doi.org/10.1093/jac/dkq109 PMID: 20375031.
10. Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G. Reduced susceptibility to host-defense cat-ionic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis. 2012; 206(8):1160–7. https://doi.org/10.1093/infdis/jis482 PMID: 22904338

11. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, et al. Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother. 2008; 52(1):269–78. https://doi.org/10.1128/AAC.00719-07 PMID: 17954690

12. Marco F, de la Maria CG, Armero Y, Amat E, Soy D, Moreno A, et al. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2008; 52(7):2538–43. https://doi.org/10.1128/AAC.00510-07 PMID: 18426900

13. Murthy MH, Olson ME, Wickert RW, Fey PD, Jalali Z. Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate. J Med Microbiol. 2008; 57(Pt 8):1036–8. https://doi.org/10.1099/jmm.0.2008/000988-0 PMID: 18628509

14. Bayer AS, Mishra NN, Chen L, Kreiswirth BN, Rubio A, Yang SJ. Frequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial Peptides. Antimicrob Agents Chemother. 2015; 59(8):4930–7. Epub 2015/06/10. https://doi.org/10.1128/AAC.00970-15 PMID: 26055370; PubMed Central PMCID: PMC4505294.

15. Bayer AS, Mishra NN, Sakoulas G, Nonejuie P, Nast CC, Pogliano J, et al. Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides. Antimicrob Agents Chemother. 2014; 58(12):7462–7. https://doi.org/10.1128/AAC.03422-14 PMID: 25288091

16. Kaatz GW, Lundstrom TS, Seo SM. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents. 2006; 28(4):280–7. Epub 2006/09/12. https://doi.org/10.1016/j.ijantimicro.2006.05.030 PMID: 16963232.

17. Yang SJ, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother. 2010; 54(8):3079–85. https://doi.org/10.1128/AAC.00122-10 PMID: 20498310

18. Mishra NN, Rubio A, Nast CC, Bayer AS. Differential Adaptations of Methicillin-Resistant Staphylococcus aureus to Serial In Vitro Passage in Daptomycin: Evolution of Daptomycin Resistance and Role of Membrane Carotenoid Content and Fluidity. Int J Microbiol. 2012; 2012:683450. https://doi.org/10.1155/2012/683450 PMID: 22956961

19. Mishra NN, Bayer AS, Weidenmaier C, Grau T, Wanner S, Stefani S, et al. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One. 2014; 9(9):e107426. https://doi.org/10.1371/journal.pone.0107426 PMID: 25226591

20. Berti AD, Wergin JE, Girdaukas GG, Hetzel SJ, Sakoulas G, Rose WE. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. Antimicrob Agents Chemother. 2012; 56(10):5046–53. https://doi.org/10.1128/AAC.00502-12 PMID: 22802248

21. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, et al. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009; 53(6):2312–8. https://doi.org/10.1128/AAC.01682-08 PMID: 19332679

22. Yang SJ, Xiong YQ, Dunman PM, Schrenzel J, Francois P, Peschel A, et al. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob Agents Chemother. 2009; 53(6):2636–7. https://doi.org/10.1128/AAC.01415-08 PMID: 19289517

23. Yang SJ, Kreiswirth BN, Sakoulas G, Yeaman MR, Xiong YQ, Sawa A, et al. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis. 2009; 200(12):1916–20. https://doi.org/10.1086/648473 PMID: 19919306

24. Bayer AS, Mishra NN, Cheung AL, Rubio A, Yang SJ. Dysregulation of mprF and dltABCD expression among daptomycin-non-susceptible MRSA clinical isolates. J Antimicrob Chemother. 2016; 71(8):2100–4. Epub 2016/04/29. https://doi.org/10.1093/jac/dkw142 PMID: 27121398; PubMed Central PMCID: PMC4954926.

25. Ernst CM, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, et al. The bacterial defense resistance protein MrpF consists of separable domains for lipid lysinylation and antimicrobial peptide
repulsion. PLoS Pathog. 2009; 5(11):e1000660. Epub 2009/11/17. https://doi.org/10.1371/journal.ppat.1000660 PMID: 19915718; PubMed Central PMCID: PMCPMC2774229.

26. Dubrac S, Bisicchia P, Devine KM, Msadek T. A matter of life and death: cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway. Mol Microbiol. 2008; 70(6):1307–22. https://doi.org/10.1111/j.1365-2958.2008.06483.x PMID: 19019149

27. Cameron DR, Mortin LI, Rubio A, Mylonakis E, Moellering RC Jr., Eliopoulos GM, et al. Impact of daptomycin resistance on Staphylococcus aureus virulence. Virulence. 2015; 6(2):127–31. Epub 2015/04/02. https://doi.org/10.1080/21555594.2015.1011532 PMID: 25830650; PubMed Central PMCID: PMCPMC4601193.

28. Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF, et al. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog. 2011; 7(11):e1002359. Epub 2011/11/22. https://doi.org/10.1371/journal.ppat.1002359 PMID: 22102812; PubMed Central PMCID: PMCPMC3213104.

29. Kopriwnjak T, Zhang D, Ernst CM, Peschel A, Nauseef WM, Weiss JP. Characterization of Staphylococcus aureus cardiolipin synthases 1 and 2 and their contribution to accumulation of cardiolipin in stationary phase and within phagocytes. J Bacteriol. 2011; 193(16):4134–42. Epub 2011/06/15. https://doi.org/10.1128/JB.00288-11 PMID: 21665977; PubMed Central PMCID: PMCPMC3147675.

30. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr., Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother. 2006; 50(4):1581–5. Epub 2006/03/30. https://doi.org/10.1128/AAC.50.4.1581-1585.2006 PMID: 16569891; PubMed Central PMCID: PMCPMC1249332.

31. Dhand A, Bayer AS, Pogliano J, Yang SJ, Borlais M, Nizet V, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011; 53(2):158–63. https://doi.org/10.1093/cid/cir340 PMID: 21690622.

32. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. Ceftriaxone increases membrane binding and enhances the activity of daptomycin against daptomycin-non-susceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013; 57(1):66–73. https://doi.org/10.1128/AAC.01586-12 PMID: 23070161.

33. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol. 2003; 41(4):1687–93. Epub 2003/04/12. https://doi.org/10.1128/JCM.41.4.1687-1693.2003 PMID: 12682161; PubMed Central PMCID: PMCPMC153915.

34. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de LH, Richardson P, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A. 2007; 104(22):9451–6. https://doi.org/10.1073/pnas.0609839104 PMID: 17517606.

35. Bayer AS, Prasad R, Chandra J, Koul A, Smriti M, Varma A, et al. In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. Infect Immun. 2000; 68(6):3548–53. Epub 2000/05/19. PMID: 10816510; PubMed Central PMCID: PMCPMC1426932.

36. Vadyvaloo V, Arous S, Gravesen A, Hechard Y, Chauhan-Haubrock R, Hastings JW, et al. Cell-surface alterations in class IIa bacteriocin-resistant Listeria monocytogenes strains. Microbiology. 2004; 150(Pt 9):3025–33. Epub 2004/09/07. https://doi.org/10.1099/mic.0.27059-0 PMID: 15347760.

37. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Gotz F. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem. 1999; 274(13):8405–10. Epub 1999/03/20. PMID: 10085071.

38. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754–60. Epub 2009/05/20. https://doi.org/10.1093/bioinformatics/btp324 PMID: 19451168; PubMed Central PMCID: PMCPMC2705234.

39. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012; 19(5):455–77. Epub 2012/04/18. https://doi.org/10.1089/cmb.2012.0021 PMID: 22506599; PubMed Central PMCID: PMCPMC3342519.

40. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014, 30(14):2068–9. Epub 2014/03/20. https://doi.org/10.1093/bioinformatics/btu153 PMID: 24642063.

41. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25(16):2078–9. https://doi.org/10.1093/bioinformatics/btp352 PMID: 19505943.
Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013; 14(2):178–92. Epub 2012/04/21. https://doi.org/10.1093/bib/bbs017 PMID: 22517427; PubMed Central PMCID: PMCPMC3603213.

Mwangi MM, Kim C, Chung M, Tsai J, Vijayadamodar G, Benitez M, et al. Whole-genome sequencing reveals a link between beta-lactam resistance and synthetases of the alarmone (p)ppGpp in Staphylococcus aureus. Microb Drug Resist. 2013; 19(3):153–9. Epub 2013/05/11. https://doi.org/10.1089/mdr.2013.0053 PMID: 23659600; PubMed Central PMCID: PMCPMC3662374.

Camerón DR, Ward DV, Kostoulas X, Howden BP, Moelling CR Jr., Eliopoulos GM, et al. Serine/threonine phosphatase Spf1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. J Infect Dis. 2012; 205(11):1677–67. Epub 2012/04/12. https://doi.org/10.1093/infdis/jis525 PMID: 22492855; PubMed Central PMCID: PMCPMC3415852.

Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol. 2006; 44(2):655–6. https://doi.org/10.1128/JCM.44.2.655-656.2006 PMID: 16455939

Bayer AS, Schneider T, Sahl HG. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci. 2013; 1277:139–58. https://doi.org/10.1111/j.1749-6632.2012.06819.x PMID: 23215859

Mehta S, Cuirolo AX, Plata KB, Riosoa S, Silverman JA, Rubio A, et al. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2012; 56(1):92–102. https://doi.org/10.1128/AAC.00432-10 PMID: 21986832

Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2006; 50(6):2137–45. https://doi.org/10.1128/AAC.00039-06 PMID: 16723576

Mishra NN, Bayer AS. Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013; 57(2):1082–5. https://doi.org/10.1128/AAC.02182-12 PMID: 23254419

Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother. 2000; 44(9):2276–85. PMID: 10952568

Cui L, Tominae E, Neoh HM, Hiramatsu K. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006; 50(3):1079–82. https://doi.org/10.1128/AAC.50.3.1079-1082.2006 PMID: 16495273

Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol. 2003; 49(3):807–21. PMID: 12864861

Dubrac S, Msadek T. Tearing down the wall: peptidoglycan metabolism and the WalK/WalR (YycG/YycF) essential two-component system. Adv Exp Med Biol. 2008; 631:214–28. https://doi.org/10.1007/978-0-387-78885-2_15 PMID: 18792692

Dubrac S, Boneca IG, Poupe l O, Msadek T. New insights into the WalK/WalR (YycG/YycF) essential signal transduction pathway reveal a major role in controlling cell wall metabolism and biofilm formation in Staphylococcus aureus. J Bacteriol. 2007; 189(22):8257–69. https://doi.org/10.1128/JB.00645-07 PMID: 17827301

Song Y, Rubio A, Jayaswal RK, Silverman JA, Wilkinson BJ. Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies. PLoS One. 2013; 8(3):e58469. https://doi.org/10.1371/journal.pone.0058469 PMID: 23554895

Pereira SF, Henriques AO, Pinho MG, de LH, Tomasz A. Evidence for a dual role of BpbP1 in the cell division and cell separation of Staphylococcus aureus. Mol Microbiol. 2009; 72(4):895–904. https://doi.org/10.1111/j.1365-2958.2009.06687.x PMID: 19400776

Boyle-Vavra S, Jones M, Gourley BL, Holmes M, Ruf R, Balsam AR, et al. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob Agents Chemother. 2011; 55(5):2018–25. https://doi.org/10.1128/AAC.01593-10 PMID: 21343446

Shoji M, Cui L, Iizuka R, Komoto A, Neoh HM, Watanabe Y, et al. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother. 2011; 55(8):3870–81. https://doi.org/10.1128/AAC.01563-10 PMID: 21628539

Borbulevych O, Kumarasiri M, Wilson B, Liarrull Li, Lee M, Heseck D, et al. Lysine Nzeta-decarboxylation switch and activation of the beta-lactam sensor domain of BlaR1 protein of methicillin-resistant Staphylococcus aureus. J Biol Chem. 2011; 286(36):31466–72. Epub 2011/07/22. https://doi.org/10.1074/jbc.M111.252189 PMID: 21775440; PubMed Central PMCID: PMCPMC3173090.
60. Szurmant H, Nelson K, Kim EJ, Perego M, Hoch JA. YycH regulates the activity of the essential YycFG two-component system in Bacillus subtilis. J Bacteriol. 2005; 187(15):5419–26. Epub 2005/07/21. https://doi.org/10.1128/JB.187.15.5419-5426.2005 PMID: 16030236; PubMed Central PMCID: PMCPMC1196008.

61. Cameron DR, Jiang JH, Kostoulia X, Foxwell DJ, Peleg AY. Vancomycin susceptibility in methicillin-resistant Staphylococcus aureus is mediated by YycHI activation of the WalRK essential two-component regulatory system. Sci Rep. 2016; 6:30823. Epub 2016/09/08. https://doi.org/10.1038/srep30823 PMID: 27600558; PubMed Central PMCID: PMCPMC5013275.

62. Hiramatsu K, Katayama Y, Matsuo M, Sasaki T, Morimoto Y, Sekiguchi A, et al. Multi-drug-resistant Staphylococcus aureus and future chemotherapy. J Infect Chemother. 2014; 20(10):593–601. Epub 2014/08/31. https://doi.org/10.1016/j.jiac.2014.08.001 PMID: 25172776.

63. Hiramatsu K, Kayayama Y, Matsuo M, Aiba Y, Saito M, Hishinuma T, et al. Vancomycin-intermediate resistance in Staphylococcus aureus. J Glob Antimicrob Resist. 2014; 2(4):213–24. Epub 2014/12/01. https://doi.org/10.1016/j.jgar.2014.04.006 PMID: 27873679.

64. Jerga A, Lu YJ, Schujman GE, de Mendoza D, Rock CO. Identification of a soluble diacylglycerol kinase required for lipoteichoic acid production in Bacillus subtilis. J Biol Chem. 2007; 282(30):21738–45. Epub 2007/05/31. https://doi.org/10.1074/jbc.M703536200 PMID: 17535816.

65. Manat G, Roure S, Auger R, Bouhss A, Barreteau H, Mengin-Lecureux D, et al. Deciphering the metabolism of undecaprenyl-phosphate: the bacterial cell-wall unit carrier at the membrane frontier. Microb Drug Resist. 2014; 20(3):199–214. Epub 2014/05/07. https://doi.org/10.1089/mdr.2014.0035 PMID: 24799078; PubMed Central PMCID: PMCPMC4050452.

66. Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, et al. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One. 2012; 7(1):e28316. Epub 2012/01/13. https://doi.org/10.1371/journal.pone.0028316 PMID: 22238576; PubMed Central PMCID: PMCPMC3253072.